Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

François Ghiringhelli

Showing results (1-10 of 346) with videos related to

Pageof 35
Sort By:
Molecular & Cellular Oncology|May 9, 2022
MAPK signaling regulates the efficacy of chemoimmunotherapyFrançois Ghiringhelli
Bulletin Du Cancer|April 30, 2018
François Ghiringhelli
Biologie Aujourd'Hui|April 12, 2019
[Combinations of chemotherapy or radiotherapy with checkpoint inhibitors]François Ghiringhelli
Bulletin Du Cancer|January 1, 2019
François Ghiringhelli
Hepatobiliary Surgery and Nutrition|April 26, 2021
Hype and hope of hepatic arterial infusion for colorectal cancerFrançois Ghiringhelli
Medecine Sciences : M/S|February 7, 2006
[Vaccine strategies against melanoma]François Ghiringhelli, Laurence Zitvogel
Frontiers in Immunology|February 16, 2026
The promise of IL-1β modulation in NSCLC clinical contextFrançois Ghiringhelli, Cédric Rébé
Genes and Immunity|December 8, 2023
Targeting CTLA-4: a possible solution for microsatellite-stable colorectal cancerFrançois Ghiringhelli, Marion Thibaudin
Immunological Reviews|August 18, 2023
Using immunogenic cell death to improve anticancer efficacy of immune checkpoint inhibitors: From basic science to clinical applicationFrançois Ghiringhelli, Cédric Rébé
Cancers|September 5, 2019
STAT3, a Master Regulator of Anti-Tumor Immune ResponseCédric Rébé, François Ghiringhelli
Pageof 35

Showing results (1-10 of 346) with videos related to

Sort By:
Pageof 35
Molecular & Cellular Oncology|May 9, 2022
MAPK signaling regulates the efficacy of chemoimmunotherapyFrançois Ghiringhelli
Bulletin Du Cancer|April 30, 2018
François Ghiringhelli
Biologie Aujourd'Hui|April 12, 2019
[Combinations of chemotherapy or radiotherapy with checkpoint inhibitors]François Ghiringhelli
Bulletin Du Cancer|January 1, 2019
François Ghiringhelli
Hepatobiliary Surgery and Nutrition|April 26, 2021
Hype and hope of hepatic arterial infusion for colorectal cancerFrançois Ghiringhelli
Medecine Sciences : M/S|February 7, 2006
[Vaccine strategies against melanoma]François Ghiringhelli, Laurence Zitvogel
Frontiers in Immunology|February 16, 2026
The promise of IL-1β modulation in NSCLC clinical contextFrançois Ghiringhelli, Cédric Rébé
Genes and Immunity|December 8, 2023
Targeting CTLA-4: a possible solution for microsatellite-stable colorectal cancerFrançois Ghiringhelli, Marion Thibaudin
Immunological Reviews|August 18, 2023
Using immunogenic cell death to improve anticancer efficacy of immune checkpoint inhibitors: From basic science to clinical applicationFrançois Ghiringhelli, Cédric Rébé
Cancers|September 5, 2019
STAT3, a Master Regulator of Anti-Tumor Immune ResponseCédric Rébé, François Ghiringhelli
Pageof 35